Arial fibrillation
More prevention than cure
Keywords:
ATRIAL FIBRILLATIONAbstract
Atrial fibrillation is the most common sustained arrhythmia. It affects 0.6% of the overall population and 6 to 8% in elderly people aged 60 to 80 years respectively. Patients with atrial fibrillation show a morbility five times higher and twice mortality rates.
This review analyzes electric and anatomy atrial remodelation. Risk factors are also discussed: age, followed by diastolic heart failure, are the most relevant risk factors. Aggresive treatment might invert structural changes provoked by hypertension, and could prevent atrial fibrillation.
Effects of non-antiarrhythmic and antiarrhythmic drugs are described. Finally we focused on primary and secondary prevention.
Atrial fibrillation is not an homogenous entity: many parameters affect initiation, perpetuation and ending ot this condition. For many patients, our goal is modest: to reduce frequency, lenght and severity of episodes; but for other patients, prevention may be definitive.
References
1) Levy S, Breithardt G, Campbell RW, Camm AJ, Daubert JC, Allessie M, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998; 19(9): 1294-320.
2) Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155(5): 469-75.
3) Prystowsky EN, Katz AM. Atrial fibrillation. In: Topol ES, ed. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven, 1998: 1827-61.
4) Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99(23): 3028-35.
5) Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5): 476-84.
6) Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74(3): 236-41.
7) Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983; 106(2): 389-96.
8) Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96(7): 2455-61.
9) Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-5.
10) Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 2002; 155(9): 819-26.
11) Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-4.
12) Lok NS, Lau CP. Presentation and management of patients admitted with atrial fibrillation: A review of 291 cases in a regional hospital. Int J Cardiol 1995; 48(3): 271-8.
13) Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van den Berg MP, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000; 21(15): 1238-45.
14) Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32(3): 695-703.
15) Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol 1998; 82(8A):18N-28N
16) Levy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns HJ, et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias of European Society of Cardiology, Working Group of Cardiac Pacing of European Society of Cardiology, North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol 2003; 14(4): 443-5.
17) Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54(2): 230-46.
18) Centurion OA, Isomoto S, Shimizu A, Konoe A, Kaibara M, Hirata T, et al. The effects of aging on atrial endocardial electrograms in patients with paroxysmal atrial fibrillation. Clin Cardiol 2003; 26(9): 435-8.
19) Evans W, Swann P. Lone auricular fibrillation. Br Heart J 1954; 16(2): 189-94.
20) Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA 1985; 254(24): 3449-53.
21) Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987; 317(11): 669-74.
22) Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95(3): 572-6.
23) Saad EB, Marrouche NF, Natale A. Ablation of focal atrial fibrillation. Card Electrophysiol Rev 2002; 6(4): 389-96.
24) Milstein S. Pautas terapéuticas para el mantenimiento de ritmo sinusal en la fibrilación auricular crónica persistente. Rev Urug Cardiol 1998, 13(1): 12-8.
25) Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7(10): 999-1007.
26) Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90(4): 400-5.
27) Bauer A, McDonald AD, Donahue JK. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 2004; 61(4): 764-70.
28) Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanism of perpetuation of atrial fibrillation. Am J Cardiol 1996; 77(3): 10A-23A.
29) Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and independent pathways. Cardiovasc Res 2003; 60(2): 315-25.
30) Schotten U, Neuberger HR, Allessie MA. The role of atrial dilatation in the domestication of atrial fibrillation. Prog Biophys Mol Biol 2003; 82(1-3): 151-62.
31) Hoit BD. Matrix metalloproteinases and atrial structural remodeling. J Am Coll Cardiol 2003; 42(2): 345-7.
32) Gronefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 2003; 8(2): 107-13.
33) Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106(6): 2091-7.
34) Wozakowska-Kaplon B, Opolski G, Janion M. Atrial natriuretic peptide before and after cardioversion of persistent atrial fibrillation. Kardiol Pol 2003; 58(4): 255-63.
35) Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardio-graphic study. J Am Coll Cardiol 2000; 35(5): 1256-62.
36) Arad M, Shotan A, Weinberger A, Aurbach I, Rabinowitz B. Plasma atrial natriuretic peptide levels for predicting the outcome of atrial fibrillation. Cardiology 2001; 95(2): 74-9.
37) Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41(2): 218-23.
38) Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003; 91(10A): 9G-14G.
39) Stollberger C, Finsterer J. Treatment of esophagitis/vagitis-induced paroxysmal atrial fibrillation by proton-pump inhibitors. J Gastroenterol 2003; 38(11): 1109.
40) Weigl M, Gschwantler M, Gatterer E, Finsterer J, Stollberger C. Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: results of a pilot study. South Med J 2003; 96(11): 1128-32.
41) Harkonen M. Vomiting, nausea and episodic atrial fibrillation Duodecim 1999; 115(24): 2795-7.
42) Brodsky MA, Orlov MV, Allen BJ, Selvan A. Frozen yogurt near deep-freeze. Am J Cardiol 1994; 73(8): 617-8.
43) Wilson CL, Davis SJ. Recurrent atrial fibrillation with nausea and vomiting. Aviat Space Environ Med 1978; 49(4): 624-5.
44) Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107(23): 2926-31.
45) Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54(2): 456-61.
46) Holtwick R, Baba HA, Ehler E, Risse D, Vobeta M, Gehrmann J, et al. Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan. J Cardiovasc Pharmacol 2002; 40(5): 725-34.
47) Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100(4): 376-80.
48) Aronson RS. Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol 1991; 2: 249-61.
49) Coumel P, Thomas O, Leenhardt A. Drug therapy for prevention of atrial fibrillation. Am J Cardiol 1996; 77(3): 3A-9A.
50) Hirayama Y, Atarashi H, Kobayashi Y, Takano T. Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation: speculation from analysis of the time course of fibrillary wave amplitudes. Jpn Heart J 2004; 45(1): 93-101.
51) Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106(3): 331-6.
52) Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease Am J Cardiol 2003; 92(12): 1379-83.
53) Korantzopoulos P, Kokkoris S. The antioxidant effects of statins may extend beyond atherosclerosis: potential benefits for atrial fibrillation and heart failure. Atherosclerosis 2004; 175(1): 187.
54) Korantzopoulos P, Kountouris E, Kolettis T, Siogas K. Anti-inflammatory and antioxidant actions of statins may favorably affect atrial remodeling in atrial fibrillation. Am J Cardiol 2004; 93(9): 1200.
55) Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92(11): 1343-5.
56) Statins becoming ever more versatile. Now also for prevention of atrial fibrillation and depression. MMW Fortschr Med 2003; 145(16): 10.
57) Futterman LG, Lemberg L. Stroke risk, cholesterol and statins. Am J Crit Care1999; 8(6): 416-9.
58) Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62(1): 105-11.
59) Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93(6): 780-2.
60) Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol 2003; 14(9 Suppl): S87-95.
61) Topol EJ, Lerman BB. Hypomagnesemic torsades de pointes. Am J Cardiol 1983; 52(10): 1367-8.
62) Gottlieb SS, Fisher ML, Pressel MD, Patten RD, Weinberg M, Greenberg N. Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. Am Heart J 1993; 125(6): 1645-50.
63) James MF, Beer RE, Esser JD. Intravenous magnesium sulfate inhibits catecholamine release associated with tracheal intubation. Anesth Analg 1989; 68(6): 772-6.
64) Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B, Graham R. An investigation of hypomagnesemia among ambulatory urban African-Americans. J Fam Pract 1999; 48(8): 636-9.
65) Topalov V, Kovacevic D, Topalov A, Kovacevic D. Magnesium in cardiology. Med Pregl 2000; 53(5-6): 319-24.
66) Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001; 94(12): 1195-201.
67) Frick M, Darpo B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2000; 21(14): 1177-85.
68) MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35(1): 30-4.
69) Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709-17.
70) Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141(10):3871-8.
71) Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17(6): 1152-6.
72) Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). RALES Investigators. Circulation 2000; 102(22): 2700-06.
73) Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10(2): 97-107.
74) Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76(17): 1259-65.
75) Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103(4): 425-31.
76) Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 2003; 16(4): 319-23.
77) Cittadini A, Casaburi C, Monti MG, Di Gianni A, Serpico R, Scherillo G, et al. Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. Cardiovasc Drugs Ther 2002; 16(3): 195-201.
78) Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274(17): 1363-7.
79) de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99(6): 779-85.
80) Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354(9177): 447-55.
81) Christensen JH, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997; 79(12): 1670-3.
82) Pepe S, McLennan PL. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 1996; 126(1): 34-42.
83) Kinoshita I, Itoh K, Nishida-Nakai M, Hirota H, Otsuji S, Shibata N. Antiarrhythmic effects of eicosapentaenoic acid during myocardial infarction-enhanced cardiac microsomal (Ca(2+)-Mg2+)-ATPase activity. Jpn Circ J 1994; 58(12): 903-12.
84) Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998; 68(1): 52-9.
85) Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Circulation 1996; 94(7): 1774-80.
86) Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106(21): 2747-57.
87) Nedostup AV, Solov’eva AD, San’kova TA. Use of clonaze-pam for treatment of patients with paroxysmal atrial fibrillation with regard to their psychoautonomic status. Ter Arkh 2003; 75(8): 35-8.
88) Bigger JT Jr. Epidemiological and mechanistic studies of atrial fibrillation as a basis for treatment strategies. Circulation 1998; 98(10): 943-5.
89) Van-Noord T, Tieleman RG, Bosker HA, Kingma T, Van-Veldhuisen DJ, Crijns HJ, et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004; 6(4): 343-50.
90) Lieberman R, Grenz D, Mond HG, Gammage MD. Selective site pacing: defining and reaching the selected site. Pacing Clin Electrophysiol 2004; 27(6 Pt 2): 883-6.
91) Padeletti L, Michelucci A, Pieragnoli P, Colella A, Musilli N. Atrial septal pacing: a new approach to prevent atrial fibrillation. Pacing Clin Electrophysiol 2004; 27(6 Pt 2): 850-4.
92) Leenhardt A, Extramiana F, Cauchemez B, Denjoy I, Maison-Blanche P, Coumel P. Role of antiarrhythmics in the treatment of paroxysmal atrial fibrillation. Arch Mal Coeur Vaiss 2002; 95 (Spec No 5): 7-13.
93) Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85(10A): 12D-19D.
94) Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994; 331(12): 785-91.
95) Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm: a meta-analysis of randomized clinical trials. Circulation 1990; 82(4): 1106-16.
96) Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117(2): 141-50.
97) Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000, 84(3): 339-46
98) Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000; 85(10A): 3D-11D.
99) Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31(2): 115-22.
100) Ben-David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 1992; 20(7): 1576-84.
101) Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342(13): 913-20.
102) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321(6): 406-12.
103) Cairns JA, Connolly SJ, Roberts R, Gent M. The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349 (9053): 675-82.
104) Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344(8921): 493-8.
105) Grosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267(24): 3289-93.
106) Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349(9053): 667-74.
107) Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF STAT Investigators. Circulation 1996; 93(12): 2128-34.
108) Hassink RJ, Aretz HT, Ruskin J, Keane D. Morphology of atrial myocardium in human pulmonary veins: a postmortem analysis in patients with and without atrial fibrillation. J Am Coll Cardiol 2003; 42(6): 1108-14.
109) Haissaguerre M, Fischer B, Labbe T, Lemetayer P, Montserrat P, d’ Ivernois C, et al. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992; 69(5): 493-7.
110) Haissaguerre M, Gencel L, Fischer B, Le Metayer P, Poquet F, Marcus FI, et al. Successful catheter ablation of atrial fíbrillation. J Cardiovasc Electrophysiol 1994; 5(12): 1045-52.
111) Seshadri N, Marrouche NF, Wilber D, Packer D, Natale A. Pulmonary vein isolation for treatment of atrial fibrillation: recent updates. Pacing Clin Electrophysiol 2003; 26(7 Pt 2): 1636-40.
112) Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109(3):327-34.
113) Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42(2): 185-97.
114) Pachon J. Atrial fibrillation treatment. North American Society of Pacing and Electrophysiology Meeting, San Francisco, May 20-22, 2004.
115) Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomized trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994; 344(8936): 1523-8.
116) Attuel P, Pellerin D, Mugica J, Coumel P. DDD pacing: an effective treatment modality for recurrent atrial arrhythmias. Pacing Clin Electrophysiol 1988; 11(11 Pt 2): 1647-54.
117) Daubert C, Mabo P, Berder V. Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronization. J Cardiovasc Pacing Electrophysiol 1994; 4: 35-44.
118) Kristensen L, Nielsen JC, Mortensen PT, Christensen PD, Vesterlund T, Pedersen AK et al. Sinus and paced P wave duration and dispersion as predictors of atrial fibrillation after pacemaker implantation in patients with isolated sick sinus syndrome. Pacing Clin Electrophysiol 2004; 27(5): 606-14.
119) Padeletti L, Purerfellner H, Adler SW, Waller TJ, Harvey M, Horvitz L, et al. Worldwide ASPECT Investigators. Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal atrial tachyarrhythmia. J Cardiovasc Electrophysiol 2003; 14(11): 1189-95.
120) Hertervig E, Yuan S, Liu S, Kongstad O, Luo J, Olsson SB. Electroanatomic mapping of transseptal conduction during coronary sinus pacing in patients with paroxysmal atrial fibrillation. Scand Cardiovasc J 2003; 37(6): 340-3.
121) Cox JL, Schuessler RB, D’Agostino HJ Jr, Stone CM, Chang BC, Cain ME, et al. The surgical treatment of atrial flbrillation. J Thorac Cardiovasc Surg 1991; 101(4): 569-83.
122) Kosakai Y, Kawaguchi AT, Isobe F, Sasako Y, Nakano K, Eishi K, et al. Modified maze procedure for patients with atrial fibrillation undergoing simultaneous open heart surgery. Circulation 1995; 92(9 Suppl): II359-64.
123) Melo JQ, Santiago T, Gouveia RH, Martins AP. Atrial ablation for the surgical treatment of atrial fibrillation: principles and limitations. J Card Surg 2004; 19(3): 207-10.
124) Melo J. Concomitant surgery for atrial fibrillation in the patient undergoing mitral surgery. Rev Esp Cardiol 2001; 54(6): 675-6.
125) Stanham R, Cura L, Pizzano N, Vignolo G, Fernández Banizi P, Casinelli M, et al. Ablación intraoperatoria de fibrilación auricular crónica por radiofrecuencia irrigada. Resultados a corto y mediano plazo. Congreso Uruguayo de Cardiología, 20. Montevideo, nov. 2004. Rev Urug Cardiol 2004; 19(2-3): 177-8.
126) Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135(12): 1061-73.
127) Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, et al. Study of Prevention of Postoperative Atrial Fibrillation. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J 2004; 147(4): 636-43.
128) Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106(1): 75-80.
129) Crystal E, Healey J, Connolly SJ. Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. Card Electrophysiol Rev 2003; 7(2): 189-92.
2) Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155(5): 469-75.
3) Prystowsky EN, Katz AM. Atrial fibrillation. In: Topol ES, ed. Textbook of Cardiovascular Medicine. Philadelphia: Lippincott-Raven, 1998: 1827-61.
4) Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99(23): 3028-35.
5) Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5): 476-84.
6) Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74(3): 236-41.
7) Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983; 106(2): 389-96.
8) Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96(7): 2455-61.
9) Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-5.
10) Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol 2002; 155(9): 819-26.
11) Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-4.
12) Lok NS, Lau CP. Presentation and management of patients admitted with atrial fibrillation: A review of 291 cases in a regional hospital. Int J Cardiol 1995; 48(3): 271-8.
13) Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van den Berg MP, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000; 21(15): 1238-45.
14) Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32(3): 695-703.
15) Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol 1998; 82(8A):18N-28N
16) Levy S, Camm AJ, Saksena S, Aliot E, Breithardt G, Crijns HJ, et al. International consensus on nomenclature and classification of atrial fibrillation: a collaborative project of the Working Group on Arrhythmias of European Society of Cardiology, Working Group of Cardiac Pacing of European Society of Cardiology, North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol 2003; 14(4): 443-5.
17) Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54(2): 230-46.
18) Centurion OA, Isomoto S, Shimizu A, Konoe A, Kaibara M, Hirata T, et al. The effects of aging on atrial endocardial electrograms in patients with paroxysmal atrial fibrillation. Clin Cardiol 2003; 26(9): 435-8.
19) Evans W, Swann P. Lone auricular fibrillation. Br Heart J 1954; 16(2): 189-94.
20) Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA 1985; 254(24): 3449-53.
21) Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med 1987; 317(11): 669-74.
22) Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95(3): 572-6.
23) Saad EB, Marrouche NF, Natale A. Ablation of focal atrial fibrillation. Card Electrophysiol Rev 2002; 6(4): 389-96.
24) Milstein S. Pautas terapéuticas para el mantenimiento de ritmo sinusal en la fibrilación auricular crónica persistente. Rev Urug Cardiol 1998, 13(1): 12-8.
25) Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7(10): 999-1007.
26) Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90(4): 400-5.
27) Bauer A, McDonald AD, Donahue JK. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 2004; 61(4): 764-70.
28) Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanism of perpetuation of atrial fibrillation. Am J Cardiol 1996; 77(3): 10A-23A.
29) Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and independent pathways. Cardiovasc Res 2003; 60(2): 315-25.
30) Schotten U, Neuberger HR, Allessie MA. The role of atrial dilatation in the domestication of atrial fibrillation. Prog Biophys Mol Biol 2003; 82(1-3): 151-62.
31) Hoit BD. Matrix metalloproteinases and atrial structural remodeling. J Am Coll Cardiol 2003; 42(2): 345-7.
32) Gronefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 2003; 8(2): 107-13.
33) Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106(6): 2091-7.
34) Wozakowska-Kaplon B, Opolski G, Janion M. Atrial natriuretic peptide before and after cardioversion of persistent atrial fibrillation. Kardiol Pol 2003; 58(4): 255-63.
35) Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardio-graphic study. J Am Coll Cardiol 2000; 35(5): 1256-62.
36) Arad M, Shotan A, Weinberger A, Aurbach I, Rabinowitz B. Plasma atrial natriuretic peptide levels for predicting the outcome of atrial fibrillation. Cardiology 2001; 95(2): 74-9.
37) Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41(2): 218-23.
38) Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003; 91(10A): 9G-14G.
39) Stollberger C, Finsterer J. Treatment of esophagitis/vagitis-induced paroxysmal atrial fibrillation by proton-pump inhibitors. J Gastroenterol 2003; 38(11): 1109.
40) Weigl M, Gschwantler M, Gatterer E, Finsterer J, Stollberger C. Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: results of a pilot study. South Med J 2003; 96(11): 1128-32.
41) Harkonen M. Vomiting, nausea and episodic atrial fibrillation Duodecim 1999; 115(24): 2795-7.
42) Brodsky MA, Orlov MV, Allen BJ, Selvan A. Frozen yogurt near deep-freeze. Am J Cardiol 1994; 73(8): 617-8.
43) Wilson CL, Davis SJ. Recurrent atrial fibrillation with nausea and vomiting. Aviat Space Environ Med 1978; 49(4): 624-5.
44) Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107(23): 2926-31.
45) Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54(2): 456-61.
46) Holtwick R, Baba HA, Ehler E, Risse D, Vobeta M, Gehrmann J, et al. Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan. J Cardiovasc Pharmacol 2002; 40(5): 725-34.
47) Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100(4): 376-80.
48) Aronson RS. Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol 1991; 2: 249-61.
49) Coumel P, Thomas O, Leenhardt A. Drug therapy for prevention of atrial fibrillation. Am J Cardiol 1996; 77(3): 3A-9A.
50) Hirayama Y, Atarashi H, Kobayashi Y, Takano T. Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation: speculation from analysis of the time course of fibrillary wave amplitudes. Jpn Heart J 2004; 45(1): 93-101.
51) Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106(3): 331-6.
52) Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease Am J Cardiol 2003; 92(12): 1379-83.
53) Korantzopoulos P, Kokkoris S. The antioxidant effects of statins may extend beyond atherosclerosis: potential benefits for atrial fibrillation and heart failure. Atherosclerosis 2004; 175(1): 187.
54) Korantzopoulos P, Kountouris E, Kolettis T, Siogas K. Anti-inflammatory and antioxidant actions of statins may favorably affect atrial remodeling in atrial fibrillation. Am J Cardiol 2004; 93(9): 1200.
55) Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92(11): 1343-5.
56) Statins becoming ever more versatile. Now also for prevention of atrial fibrillation and depression. MMW Fortschr Med 2003; 145(16): 10.
57) Futterman LG, Lemberg L. Stroke risk, cholesterol and statins. Am J Crit Care1999; 8(6): 416-9.
58) Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62(1): 105-11.
59) Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93(6): 780-2.
60) Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol 2003; 14(9 Suppl): S87-95.
61) Topol EJ, Lerman BB. Hypomagnesemic torsades de pointes. Am J Cardiol 1983; 52(10): 1367-8.
62) Gottlieb SS, Fisher ML, Pressel MD, Patten RD, Weinberg M, Greenberg N. Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. Am Heart J 1993; 125(6): 1645-50.
63) James MF, Beer RE, Esser JD. Intravenous magnesium sulfate inhibits catecholamine release associated with tracheal intubation. Anesth Analg 1989; 68(6): 772-6.
64) Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B, Graham R. An investigation of hypomagnesemia among ambulatory urban African-Americans. J Fam Pract 1999; 48(8): 636-9.
65) Topalov V, Kovacevic D, Topalov A, Kovacevic D. Magnesium in cardiology. Med Pregl 2000; 53(5-6): 319-24.
66) Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J 2001; 94(12): 1195-201.
67) Frick M, Darpo B, Ostergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2000; 21(14): 1177-85.
68) MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35(1): 30-4.
69) Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709-17.
70) Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141(10):3871-8.
71) Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17(6): 1152-6.
72) Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). RALES Investigators. Circulation 2000; 102(22): 2700-06.
73) Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10(2): 97-107.
74) Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76(17): 1259-65.
75) Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103(4): 425-31.
76) Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 2003; 16(4): 319-23.
77) Cittadini A, Casaburi C, Monti MG, Di Gianni A, Serpico R, Scherillo G, et al. Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. Cardiovasc Drugs Ther 2002; 16(3): 195-201.
78) Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274(17): 1363-7.
79) de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99(6): 779-85.
80) Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354(9177): 447-55.
81) Christensen JH, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997; 79(12): 1670-3.
82) Pepe S, McLennan PL. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 1996; 126(1): 34-42.
83) Kinoshita I, Itoh K, Nishida-Nakai M, Hirota H, Otsuji S, Shibata N. Antiarrhythmic effects of eicosapentaenoic acid during myocardial infarction-enhanced cardiac microsomal (Ca(2+)-Mg2+)-ATPase activity. Jpn Circ J 1994; 58(12): 903-12.
84) Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998; 68(1): 52-9.
85) Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Circulation 1996; 94(7): 1774-80.
86) Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106(21): 2747-57.
87) Nedostup AV, Solov’eva AD, San’kova TA. Use of clonaze-pam for treatment of patients with paroxysmal atrial fibrillation with regard to their psychoautonomic status. Ter Arkh 2003; 75(8): 35-8.
88) Bigger JT Jr. Epidemiological and mechanistic studies of atrial fibrillation as a basis for treatment strategies. Circulation 1998; 98(10): 943-5.
89) Van-Noord T, Tieleman RG, Bosker HA, Kingma T, Van-Veldhuisen DJ, Crijns HJ, et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004; 6(4): 343-50.
90) Lieberman R, Grenz D, Mond HG, Gammage MD. Selective site pacing: defining and reaching the selected site. Pacing Clin Electrophysiol 2004; 27(6 Pt 2): 883-6.
91) Padeletti L, Michelucci A, Pieragnoli P, Colella A, Musilli N. Atrial septal pacing: a new approach to prevent atrial fibrillation. Pacing Clin Electrophysiol 2004; 27(6 Pt 2): 850-4.
92) Leenhardt A, Extramiana F, Cauchemez B, Denjoy I, Maison-Blanche P, Coumel P. Role of antiarrhythmics in the treatment of paroxysmal atrial fibrillation. Arch Mal Coeur Vaiss 2002; 95 (Spec No 5): 7-13.
93) Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85(10A): 12D-19D.
94) Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994; 331(12): 785-91.
95) Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm: a meta-analysis of randomized clinical trials. Circulation 1990; 82(4): 1106-16.
96) Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117(2): 141-50.
97) Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000, 84(3): 339-46
98) Prystowsky EN. Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000; 85(10A): 3D-11D.
99) Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31(2): 115-22.
100) Ben-David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 1992; 20(7): 1576-84.
101) Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342(13): 913-20.
102) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321(6): 406-12.
103) Cairns JA, Connolly SJ, Roberts R, Gent M. The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997; 349 (9053): 675-82.
104) Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344(8921): 493-8.
105) Grosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267(24): 3289-93.
106) Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349(9053): 667-74.
107) Massie BM, Fisher SG, Radford M, Deedwania PC, Singh BN, Fletcher RD, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF STAT Investigators. Circulation 1996; 93(12): 2128-34.
108) Hassink RJ, Aretz HT, Ruskin J, Keane D. Morphology of atrial myocardium in human pulmonary veins: a postmortem analysis in patients with and without atrial fibrillation. J Am Coll Cardiol 2003; 42(6): 1108-14.
109) Haissaguerre M, Fischer B, Labbe T, Lemetayer P, Montserrat P, d’ Ivernois C, et al. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992; 69(5): 493-7.
110) Haissaguerre M, Gencel L, Fischer B, Le Metayer P, Poquet F, Marcus FI, et al. Successful catheter ablation of atrial fíbrillation. J Cardiovasc Electrophysiol 1994; 5(12): 1045-52.
111) Seshadri N, Marrouche NF, Wilber D, Packer D, Natale A. Pulmonary vein isolation for treatment of atrial fibrillation: recent updates. Pacing Clin Electrophysiol 2003; 26(7 Pt 2): 1636-40.
112) Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004; 109(3):327-34.
113) Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42(2): 185-97.
114) Pachon J. Atrial fibrillation treatment. North American Society of Pacing and Electrophysiology Meeting, San Francisco, May 20-22, 2004.
115) Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomized trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994; 344(8936): 1523-8.
116) Attuel P, Pellerin D, Mugica J, Coumel P. DDD pacing: an effective treatment modality for recurrent atrial arrhythmias. Pacing Clin Electrophysiol 1988; 11(11 Pt 2): 1647-54.
117) Daubert C, Mabo P, Berder V. Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronization. J Cardiovasc Pacing Electrophysiol 1994; 4: 35-44.
118) Kristensen L, Nielsen JC, Mortensen PT, Christensen PD, Vesterlund T, Pedersen AK et al. Sinus and paced P wave duration and dispersion as predictors of atrial fibrillation after pacemaker implantation in patients with isolated sick sinus syndrome. Pacing Clin Electrophysiol 2004; 27(5): 606-14.
119) Padeletti L, Purerfellner H, Adler SW, Waller TJ, Harvey M, Horvitz L, et al. Worldwide ASPECT Investigators. Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal atrial tachyarrhythmia. J Cardiovasc Electrophysiol 2003; 14(11): 1189-95.
120) Hertervig E, Yuan S, Liu S, Kongstad O, Luo J, Olsson SB. Electroanatomic mapping of transseptal conduction during coronary sinus pacing in patients with paroxysmal atrial fibrillation. Scand Cardiovasc J 2003; 37(6): 340-3.
121) Cox JL, Schuessler RB, D’Agostino HJ Jr, Stone CM, Chang BC, Cain ME, et al. The surgical treatment of atrial flbrillation. J Thorac Cardiovasc Surg 1991; 101(4): 569-83.
122) Kosakai Y, Kawaguchi AT, Isobe F, Sasako Y, Nakano K, Eishi K, et al. Modified maze procedure for patients with atrial fibrillation undergoing simultaneous open heart surgery. Circulation 1995; 92(9 Suppl): II359-64.
123) Melo JQ, Santiago T, Gouveia RH, Martins AP. Atrial ablation for the surgical treatment of atrial fibrillation: principles and limitations. J Card Surg 2004; 19(3): 207-10.
124) Melo J. Concomitant surgery for atrial fibrillation in the patient undergoing mitral surgery. Rev Esp Cardiol 2001; 54(6): 675-6.
125) Stanham R, Cura L, Pizzano N, Vignolo G, Fernández Banizi P, Casinelli M, et al. Ablación intraoperatoria de fibrilación auricular crónica por radiofrecuencia irrigada. Resultados a corto y mediano plazo. Congreso Uruguayo de Cardiología, 20. Montevideo, nov. 2004. Rev Urug Cardiol 2004; 19(2-3): 177-8.
126) Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135(12): 1061-73.
127) Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, et al. Study of Prevention of Postoperative Atrial Fibrillation. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J 2004; 147(4): 636-43.
128) Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106(1): 75-80.
129) Crystal E, Healey J, Connolly SJ. Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. Card Electrophysiol Rev 2003; 7(2): 189-92.
Published
2005-12-30
How to Cite
1.
Vanerio Balbela G, Banina Aguerre D, Vidal Amaral JL, Fernández Banizi P, Vanerio de León A, López Achigar G. Arial fibrillation: More prevention than cure. Rev. Méd. Urug. [Internet]. 2005 Dec. 30 [cited 2024 Nov. 23];21(4):269-81. Available from: https://revista.rmu.org.uy/index.php/rmu/article/view/790
Issue
Section
Review or Update and Updates
